T-Cells specific clones against signal peptide domains are less likely to be exhausted in cancer patients. They possess a greater likelihood of being more potent at killing cancer cells when compared with other epitopes. This has already been validated for MUC1 in multiple myeloma cancer patients through Vaxil’s clinical trials to date.
VAXIL – Creating the ideal immunotherapy
Inducing a Broad
Cancer ResistanceLearn More
Immune ResponseLearn More
Cancer Stem CellsLearn More
First Ever SP-Specific
Antibody PlatformLearn More
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is its ImMucin™ lead immunotherapy product.